<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/355a" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/355a/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/355a/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_355a"><akn:num>355a</akn:num><akn:heading>Pediatric studies of drugs</akn:heading><akn:content><akn:p>§ 355a. Pediatric studies of drugs(a) DefinitionsAs used in this section, the term “pediatric studies” or “studies” means at least one clinical investigation (that, at the Secretary’s discretion, may include pharmacokinetic studies) in pediatric age groups (including neonates in appropriate cases) in which a drug is anticipated to be used, and, at the discretion of the Secretary, may include preclinical studies.


(b) Market exclusivity for new drugs(1) In generalExcept as provided in paragraph (2), if, prior to approval of an application that is submitted under section 355(b)(1) of this title, the Secretary determines that information relating to the use of a new drug in the pediatric population may produce health benefits in that population, the Secretary makes a written request for pediatric studies (which shall include a timeframe for completing such studies), the applicant agrees to the request, such studies are completed using appropriate formulations for each age group for which the study is requested within any such timeframe, and the reports thereof are submitted and accepted in accordance with subsection (d)(4)—(A)(i)(I) the period referred to in subsection (c)(3)(E)(ii) of section 355 of this title, and in subsection (j)(5)(F)(ii) of such section, is deemed to be five years and six months rather than five years, and the references in subsections (c)(3)(E)(ii) and (j)(5)(F)(ii) of such section to four years, to forty-eight months, and to seven and one-half years are deemed to be four and one-half years, fifty-four months, and eight years, respectively; or

(II) the period referred to in clauses (iii) and (iv) of subsection (c)(3)(E) of such section, and in clauses (iii) and (iv) of subsection (j)(5)(F) of such section, is deemed to be three years and six months rather than three years; and


(ii) if the drug is designated under section 360bb of this title for a rare disease or condition, the period referred to in section 360cc(a) of this title is deemed to</akn:p></akn:content><akn:subsection eId="subsec_355a_a"><akn:num>(a)</akn:num><akn:heading>Definitions</akn:heading><akn:content><akn:p>(a) Definitions As used in this section, the term “pediatric studies” or “studies” means at least one clinical investigation (that, at the Secretary’s discretion, may include pharmacokinetic studies) in pediatric age groups (including neonates in appropriate cases) in which a drug is anticipated to be used, and, at the discretion of the Secretary, may include preclinical studies.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355a_b"><akn:num>(b)</akn:num><akn:heading>Market exclusivity for new drugs</akn:heading><akn:content><akn:p>(b) Market exclusivity for new drugs</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355a_c"><akn:num>(c)</akn:num><akn:heading>Market exclusivity for already-marketed drugs</akn:heading><akn:content><akn:p>(c) Market exclusivity for already-marketed drugs</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355a_d"><akn:num>(d)</akn:num><akn:heading>Conduct of pediatric studies</akn:heading><akn:content><akn:p>(d) Conduct of pediatric studies</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355a_e"><akn:num>(e)</akn:num><akn:heading>Notice of determinations on studies requirement</akn:heading><akn:content><akn:p>(e) Notice of determinations on studies requirement</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355a_f"><akn:num>(f)</akn:num><akn:heading>Internal review of written requests and pediatric studies</akn:heading><akn:content><akn:p>(f) Internal review of written requests and pediatric studies</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355a_g"><akn:num>(g)</akn:num><akn:heading>Limitations</akn:heading><akn:content><akn:p>(g) Limitations Notwithstanding subsection (c)(2), a drug to which the six-month period under subsection (b) or (c) has already been applied—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355a_h"><akn:num>(h)</akn:num><akn:heading>Relationship to pediatric research requirements</akn:heading><akn:content><akn:p>(h) Relationship to pediatric research requirements Exclusivity under this section shall only be granted for the completion of a study or studies that are the subject of a written request and for which reports are submitted and accepted in accordance with subsection (d)(4). Written requests under this section may consist of a study or studies required under section 355c of this title.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355a_i"><akn:num>(i)</akn:num><akn:heading>Labeling changes</akn:heading><akn:content><akn:p>(i) Labeling changes</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355a_j"><akn:num>(j)</akn:num><akn:heading>Other labeling changes</akn:heading><akn:content><akn:p>(j) Other labeling changes If, on or after September 27, 2007, the Secretary determines that a pediatric study conducted under this section does or does not demonstrate that the drug that is the subject of the study is safe and effective, including whether such study results are inconclusive, in pediatric populations or subpopulations, the Secretary shall order the labeling of such product to include information about the results of the study and a statement of the Secretary’s determination.</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>